0.6422

0.34% -0.0022

After Hours: .64 -0.0022 -0.34%

Werewolf Therapeutics Inc (HOWL)

Overview News Price History Option Chain Financials Discussions Forecast

Werewolf Therapeutics Inc stock is traded at $0.6422, with a volume of 352.33K. It is down -0.34% in the last 24 hours and down -32.52% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Previous Close:

$0.6444

Open:

$0.641

24h Volume:

352.33K

Relative Volume:

0.39

Market Cap:

$31.17M

Revenue:

$19.94M

Net Income/Loss:

$-37.37M

P/E Ratio:

-0.6175

EPS:

-1.04

Net Cash Flow:

$-33.38M

1W Performance:

+5.05%

1M Performance:

-32.52%

6M Performance:

-39.98%

1Y Performance:

-60.36%

1-Day Range:

$0.64

$0.67

1-Week Range:

$0.60

$0.67

52-Week Range:

$0.5588

$2.38

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name

Werewolf Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

617-952-0555

Address

200 TALCOTT AVENUE, WATERTOWN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HOWL Werewolf Therapeutics Inc	0.6422	31.28M	19.94M	-37.37M	-33.38M	-1.04
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Downgrade	Wedbush	Outperform → Neutral
Apr-03-24	Initiated	JMP Securities	Mkt Outperform
Aug-24-23	Initiated	Wedbush	Outperform
Jun-06-23	Resumed	Jefferies	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-25-21	Initiated	Evercore ISI	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy
May-25-21	Initiated	Jefferies	Buy
May-25-21	Initiated	SVB Leerink	Outperform

View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

Jan 04, 2026

Luke Evnin Sells 34,847 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - Defense World

Jan 04, 2026

Dec 29, 2025

Will Werewolf Therapeutics Inc. stock return to pre crisis levelsAnalyst Upgrades & Capital Efficiency Improvement - bollywoodhelpline.com

Dec 29, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of “Hold” from Analysts - Defense World

Dec 29, 2025

Dec 22, 2025

Market Moves: Is Werewolf Therapeutics Inc. stock ready for breakoutWeekly Trade Summary & Real-Time Stock Price Movement Reports - moha.gov.vn

Dec 22, 2025

Dec 20, 2025

Will Werewolf Therapeutics Inc. stock benefit from infrastructure spendingProduct Launch & Free Accurate Trade Setup Notifications - Улправда

Dec 20, 2025

Is Werewolf Therapeutics Inc. stock ready for breakoutJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - Улправда

Dec 20, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Downgraded to “Neutral” Rating by Wedbush - Defense World

Dec 20, 2025

Why retail investors pile into Werewolf Therapeutics Inc. stockRisk Management & Technical Confirmation Trade Alerts - Улправда

Dec 20, 2025

Dec 19, 2025

HC Wainwright & Co. Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - Nasdaq

Dec 19, 2025

H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update By Investing.com - Investing.com Nigeria

Dec 19, 2025

Can Werewolf Therapeutics Inc. stock hit analyst price targetsOil Prices & Capital Protection Trading Alerts - DonanımHaber

Dec 19, 2025

Wedbush Downgrades Werewolf Therapeutics to Neutral From Outperform Due to 'Forward Challenging' Path, Cuts Price Target to $1 From $3 - marketscreener.com

Dec 19, 2025

H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update - Investing.com Nigeria

Dec 19, 2025

Werewolf Therapeutics advances Inducer platform candidates - BioWorld MedTech

Dec 19, 2025

Dec 18, 2025

Werewolf Therapeutics Announces Pipeline and Business Updates - Investing News Network

Dec 18, 2025

Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities - TipRanks

Dec 18, 2025

Werewolf Therapeutics Incplans for two INDs by mid-2027 - marketscreener.com

Dec 18, 2025

Werewolf Therapeutics, Inc. Announces Pipeline Update and 2026 Priorities - TradingView — Track All Markets

Dec 18, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Dec 18, 2025

Dec 17, 2025

Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 14,548 Shares of Stock - MarketBeat

Dec 17, 2025

Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 9,983 Shares of Stock - MarketBeat

Dec 17, 2025

Dec 16, 2025

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why - MSN

Dec 16, 2025

Dec 15, 2025

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - sharewise.com

Dec 15, 2025

Dec 14, 2025

What analysts say about Werewolf Therapeutics Inc stockInsider Trading Activity & Free Superior Stock Performance - earlytimes.in

Dec 14, 2025

Dec 13, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares - MarketBeat

Dec 13, 2025

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat

Dec 13, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $29,969.63 in Stock - MarketBeat

Dec 13, 2025

Dec 12, 2025